Biohaven points up Nurtec dual-migraine approval with growing stable of celebrity users
Biohaven Pharmaceuticals is flexing its migraine share leapfrog over powerhouse AbbVie—thanks to Nurtec ODT's dual acute-plus-prevention nod and an aggressive digital...
Continue Reading →
